1388842-44-1

Basic information

• Product Name: (Z)-3-(3-(3,5-bis(trifluoroMethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylic acid
• Synonyms: (Z)-3-(3-(3,5-bis(trifluoroMethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylic acid;2-Propenoic acid, 3-[3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]-, (2Z)-;(2Z)-3-[3-[3,5-Bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]-2-propenoic acid
• CAS NO: 1388842-44-1
• Molecular Formula: C₁₃H₇F₆N₃O₂
• Molecular Weight: 351.2039992
• EINECS: -0
• Mol File: 1388842-44-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (Z)-3-(3-(3,5-bis(trifluoroMethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (Z)-3-(3-(3,5-bis(trifluoroMethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylic acid(1388842-44-1)
• EPA Substance Registry System: (Z)-3-(3-(3,5-bis(trifluoroMethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylic acid(1388842-44-1)

Safety Data

• Hazardous Substances Data: 1388842-44-1(Hazardous Substances Data)

Usage

Uses

Used in Agricultural Industry:
BPTAA is utilized as a fungicidal agent for the protection of crops against a variety of fungal diseases. Its application is aimed at inhibiting the growth of fungi, thereby reducing crop losses and improving yield quality. The low environmental impact of BPTAA makes it an eco-friendly alternative to traditional fungicides, contributing to sustainable agricultural practices.
Used in Crop Protection:
As a component of crop protection strategies, BPTAA is employed to safeguard crops from the detrimental effects of fungal infections. Its high efficacy in controlling fungi ensures that crops remain healthy and productive, leading to enhanced agricultural output and food security.
Used in Sustainable Agriculture:
BPTAA's low environmental impact and high thermal stability make it a suitable choice for sustainable agriculture. It allows for the reduction of chemical inputs in farming while maintaining effective crop protection, aligning with the goals of sustainable and environmentally conscious farming practices.

Upstream product

• 1333154-10-1 3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazole 
• 22227-26-5 3,5-Bis(trifluoromethyl)benzamide 
• 1388842-43-0 isopropyl 3-iodoacrylate 
• 317319-15-6 3,5-bis(trifluoromethyl)benzothioamide 
• 27126-93-8 3,5-bis(trifluoromethyl)benzonitrile 
• 1333152-22-9 (Z)-isopropyl 3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylate 

Downstream Products

• 1388842-52-1 (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylic (isobutyl carbonic) anhydride 
• 1388842-26-9 (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylohydrazide 
• 1388841-50-6 (Z)-2-(2-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)vinyl)-1,3,4-oxadiazole 
• 1421919-75-6 (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(3,3-difluoroazetidin-1-yl)prop-2-en-1-one 
• 1393477-72-9 3-[3-[3,5-bis(trifloromoethyl)phenyl]-1H-1,2,4-triazol-1-yl]-N’-(pyrazin-2-yl)acrylohydrazide 
• 1392136-43-4 (Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-N'-pyridin-2-ylprop-2-enehydrazide 
• 1421920-37-7 C₁₈H₁₆F₆N₄O₂ 
• 1421923-74-1 C₁₇H₁₅F₆N₅O 
• 1421923-75-2 C₁₉H₁₄F₆N₆O 
• 1421923-76-3 C₁₈H₁₃F₆N₇O 
• 1421923-79-6 C₁₉H₁₄F₆N₆O 
• 1421923-80-9 C₁₇H₁₀ClF₆N₇O 
• 1421923-81-0 C₁₈H₁₂F₆N₆O 
• 1421923-82-1 C₂₁H₁₃F₆N₇O 

Relevant articles and documents

Preparation method of selinexor and intermediate thereof

The invention relates to a preparation method of selinexor and an intermediate thereof, which has the advantages of short synthetic route, mild reaction conditions, no foul gas generation in the reaction process, high safety, wide acceptable range of vari

Acryloyl group-containing nuclear transport modulator and uses thereof

The invention relates to a novel acryloyl-containing compound as well as a preparation method and application thereof. Specifically, the invention relates to an acryloyl-containing compound as shown in a formula (1) and a preparation method thereof, and a

PROCESS FOR PREPARING XPO1 INHIBITORS AND INTERMEDIATES FOR USE IN THE PREPARATION OF XP01 INHIBITORS

The present invention provides an improved process for preparation of the (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylic acid (referred to as compound of the structural formula (III)), which is a useful key intermediate for the sy

NOVEL CRYSTALLINE FORMS OF SELINEXOR AND PROCESS FOR THEIR PREPARATION

The present disclosure relates to solid state forms of Selinexor, processes for preparation thereof and pharmaceutical compositions thereof.

SOLID FORMS OF SELINEXOR AND PROCESS FOR THEIR PREPARATION

Aspects of the present application relate to solid forms of Selinexor, processes for their preparation and pharmaceutical compositions thereof. Specific aspects relate to crystalline and amorphous forms of Selinexor.

NUCLEAR TRANSPORT MODULATORS AND USES THEREOF

The present invention relates to compounds of Structural Formulas (I), (II) and (III): or their pharmaceutically acceptable salts; pharmaceutical compositions comprising the compounds of Structural Formulas (I), (II) and (III); and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRMl activity. The values for the variables in Structural Formulas (I), (II) and (III) are as described and defined herein.

HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF

The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

NUCLEAR TRANSPORT MODULATORS AND USES THEREOF

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.